Noriko Shimasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noriko Shimasaki has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Lip Kun Tan
National University Cancer Institute, National University Hospital, National University Health System, Singapore, Singapore
3 shared publications- Boon Cher Goh
Cancer Science Institute of Singapore, National University of Singapore, Singapore
2 shared publications Dario Campana
Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
2 shared publications- Dario Campana
Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications Elaine Coustan-Smith
Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
2 shared publications- Liang Piu Koh
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (8) , 102778
Manufacturing strategies for prolonged CAR-T cell persistence
- 11 March 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (8) , 102778
Open AccessManufacturing strategies for prolonged CAR-T cell persistence
- 3 September 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (12) , 3687-3696
Fratricide-resistant CD7-CAR T cells in T-ALL
T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (CAR) T cells expressing an anti-CD7 CAR and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Despite high leukemic burden and low CAR T cell dosing, 16 of the 17 patients attained minimal residual disease-negative complete remission within 1 month. The remaining patient had CD7− T-ALL cells before infusion, which persisted after infusion. Toxicities were mild: cytokine release syndrome grade 1 in ten patients and grade 2 in three patients; immune effector cell-associated neurotoxicity syndrome grade 1 in two patients. Eleven patients remained relapse-free (median follow-up, 15 months), including all nine patients who received an allotransplant. The first patient is in remission 55 months after infusion without further chemotherapy or transplantation; circulating CAR T cells were detectable for 2 years. T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL.
- 3 September 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (12) , 3687-3696
Fratricide-resistant CD7-CAR T cells in T-ALL
T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (CAR) T cells expressing an anti-CD7 CAR and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Despite high leukemic burden and low CAR T cell dosing, 16 of the 17 patients attained minimal residual disease-negative complete remission within 1 month. The remaining patient had CD7− T-ALL cells before infusion, which persisted after infusion. Toxicities were mild: cytokine release syndrome grade 1 in ten patients and grade 2 in three patients; immune effector cell-associated neurotoxicity syndrome grade 1 in two patients. Eleven patients remained relapse-free (median follow-up, 15 months), including all nine patients who received an allotransplant. The first patient is in remission 55 months after infusion without further chemotherapy or transplantation; circulating CAR T cells were detectable for 2 years. T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL.
- 9 September 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (12) , 1338-1348
Size control of induced pluripotent stem cells colonies in two-dimensional culture for differentiation into functional monocyte-like cells
- 9 September 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (12) , 1338-1348
Size control of induced pluripotent stem cells colonies in two-dimensional culture for differentiation into functional monocyte-like cells
- Open Access
- 1 August 2022
- Published by Fuji Technology Press Ltd. in Journal of Disaster Research
- Vol. 17 (5) , 839-840
Erratum for “The Importance of Monitoring Viral Respiratory Infections During the COVID-19 Crisis” (Vol.17, pp. 73-81, 2022)
Due to an authors’ error, the original version of this article contained errors in in-text citations under Section 4.4 and the corresponding references. Reference [55] should be listed as [56] and the following paper should be listed as [55]. K. P. Tao, M. Chong, J. C. S. Pun, J. G. S. Tsun, S. M. W. Chow, C. S. H. Ng, M. H. T. Wang, Z. Chan, P. K. S. Chan, A. M. Li, and R. W. Y. Chan, “Suppression of influenza virus infection by rhinovirus interference at the population, individual and cellular levels,” medRxiv, doi: 10.1101/2021.08.09.21256656, 2021. The two paragraphs in Section 4.4 (pp. 79–80) should be corrected as follows: Now reads Co-infections of the influenza virus and rhinovirus are relatively common, especially in young children. Previous infection with rhinovirus inhibits subsequent influenza A virus infection by the IFN-mediated innate immune system in differentiated human airway epithelium (Fig. 17) [7]. In other words, rhinovirus induces an IFN response that suppresses subsequent influenza virus infection [7]. A recent study revealed that the replication of rhinovirus is not affected by SARS-CoV-2, although the replication of SARS-CoV-2 is inhibited by rhinovirus, indicating that rhinovirus infection protects against SARS-CoV-2 [55]. SARS-CoV-2, similar to the influenza virus and many other viruses, is inhibited by IFNs [55]. Therefore, the number of COVID-19 cases may be reduced due to the inhibitory effects of rhinovirus-induced IFN response. Should read Co-infections of the influenza virus and rhinovirus are relatively common, especially in young children. Previous infection with rhinovirus inhibits subsequent influenza A virus infection by the IFN-mediated innate immune system in differentiated human airway epithelium [7]. An another study also reported similar phenomenon (Fig. 17) [55]. In other words, rhinovirus induces an IFN response that suppresses subsequent influenza virus infection [7]. A recent study revealed that the replication of rhinovirus is not affected by SARS-CoV-2, although the replication of SARS-CoV-2 is inhibited by rhinovirus, indicating that rhinovirus infection protects against SARS-CoV-2 [56]. SARS-CoV-2, similar to the influenza virus and many other viruses, is inhibited by IFNs [56]. Therefore, the number of COVID-19 cases may be reduced due to the inhibitory effects of rhinovirus-induced IFN response. In the Reference list (p. 81), references [55] to [56] should be corrected as follows: Now reads [55] K. Dee, D. M. Goldfarb, J. Haney, J. A. R. Amat, V. Herder, M. Stewart, A. M. Szemiel, M. Baguelin, and P. R. Murcia, “Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: Implications for COVID-19 epidemiology,” J. Infect. Dis., Vol.224, No.1, pp. 31-38, 2021. Should read [55] K. P. Tao, M. Chong, J. C. S. Pun, J. G. S. Tsun, S. M. W. Chow, C. S. H. Ng, M. H. T. Wang, Z. Chan, P. K. S. Chan, A. M. Li, and R. W. Y. Chan, “Suppression of influenza virus infection by rhinovirus interference at the population, individual and cellular levels,” medRxiv, doi: 10.1101/ 2021.08.09.21256656, 2021. [56] K. Dee, D. M. Goldfarb, J. Haney, J. A. R. Amat, V. Herder, M. Stewart, A. M. Szemiel, M. Baguelin, and P. R. Murcia, “Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: Implications for COVID-19 epidemiology,” J. Infect. Dis., Vol.224, No.1, pp. 31-38, 2021. The authors regret these errors, and these errors have now been corrected in the PDF version of the article.
- 1 August 2022
- Published by Fuji Technology Press Ltd. in Journal of Disaster Research
- Vol. 17 (5) , 839-840
Open AccessErratum for “The Importance of Monitoring Viral Respiratory Infections During the COVID-19 Crisis” (Vol.17, pp. 73-81, 2022)
Due to an authors’ error, the original version of this article contained errors in in-text citations under Section 4.4 and the corresponding references. Reference [55] should be listed as [56] and the following paper should be listed as [55]. K. P. Tao, M. Chong, J. C. S. Pun, J. G. S. Tsun, S. M. W. Chow, C. S. H. Ng, M. H. T. Wang, Z. Chan, P. K. S. Chan, A. M. Li, and R. W. Y. Chan, “Suppression of influenza virus infection by rhinovirus interference at the population, individual and cellular levels,” medRxiv, doi: 10.1101/2021.08.09.21256656, 2021. The two paragraphs in Section 4.4 (pp. 79–80) should be corrected as follows: Now reads Co-infections of the influenza virus and rhinovirus are relatively common, especially in young children. Previous infection with rhinovirus inhibits subsequent influenza A virus infection by the IFN-mediated innate immune system in differentiated human airway epithelium (Fig. 17) [7]. In other words, rhinovirus induces an IFN response that suppresses subsequent influenza virus infection [7]. A recent study revealed that the replication of rhinovirus is not affected by SARS-CoV-2, although the replication of SARS-CoV-2 is inhibited by rhinovirus, indicating that rhinovirus infection protects against SARS-CoV-2 [55]. SARS-CoV-2, similar to the influenza virus and many other viruses, is inhibited by IFNs [55]. Therefore, the number of COVID-19 cases may be reduced due to the inhibitory effects of rhinovirus-induced IFN response. Should read Co-infections of the influenza virus and rhinovirus are relatively common, especially in young children. Previous infection with rhinovirus inhibits subsequent influenza A virus infection by the IFN-mediated innate immune system in differentiated human airway epithelium [7]. An another study also reported similar phenomenon (Fig. 17) [55]. In other words, rhinovirus induces an IFN response that suppresses subsequent influenza virus infection [7]. A recent study revealed that the replication of rhinovirus is not affected by SARS-CoV-2, although the replication of SARS-CoV-2 is inhibited by rhinovirus, indicating that rhinovirus infection protects against SARS-CoV-2 [56]. SARS-CoV-2, similar to the influenza virus and many other viruses, is inhibited by IFNs [56]. Therefore, the number of COVID-19 cases may be reduced due to the inhibitory effects of rhinovirus-induced IFN response. In the Reference list (p. 81), references [55] to [56] should be corrected as follows: Now reads [55] K. Dee, D. M. Goldfarb, J. Haney, J. A. R. Amat, V. Herder, M. Stewart, A. M. Szemiel, M. Baguelin, and P. R. Murcia, “Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: Implications for COVID-19 epidemiology,” J. Infect. Dis., Vol.224, No.1, pp. 31-38, 2021. Should read [55] K. P. Tao, M. Chong, J. C. S. Pun, J. G. S. Tsun, S. M. W. Chow, C. S. H. Ng, M. H. T. Wang, Z. Chan, P. K. S. Chan, A. M. Li, and R. W. Y. Chan, “Suppression of influenza virus infection by rhinovirus interference at the population, individual and cellular levels,” medRxiv, doi: 10.1101/ 2021.08.09.21256656, 2021. [56] K. Dee, D. M. Goldfarb, J. Haney, J. A. R. Amat, V. Herder, M. Stewart, A. M. Szemiel, M. Baguelin, and P. R. Murcia, “Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: Implications for COVID-19 epidemiology,” J. Infect. Dis., Vol.224, No.1, pp. 31-38, 2021. The authors regret these errors, and these errors have now been corrected in the PDF version of the article.
- 29 March 2022
- Published by Springer Nature
- Vol. 2463, 311-328
Gene Transduction of Natural Killer Cells for Clinical Application
Autologous T cells expressing chimeric antigen receptor (CAR) have produced a spectacular response in hematological malignancies. This success of cellular therapy has inspired the exploration of the therapeutic potential of other immune cell types. In this regard, natural killer (NK) cells hold great potential as they can identify tumor cells by mechanisms that are different from those used by T cells and have a high cytotoxic capacity. Their capacity to recognize tumors and killing potency can be further enhanced by genetic modification. Our laboratory has developed a clinically adaptable method to manufacture genetically modified NK cells using retroviral vectors in compliance with current good manufacturing practice regulations. Here, we describe relevant technical procedures, including isolation of peripheral blood mononucleated cells from a leukapheresis product, T-cell depletion, stimulation and transduction of NK cells, and preparation of transduced NK cells for infusion.
- 29 March 2022
- Published by Springer Nature
- Vol. 2463, 311-328
Gene Transduction of Natural Killer Cells for Clinical Application
Autologous T cells expressing chimeric antigen receptor (CAR) have produced a spectacular response in hematological malignancies. This success of cellular therapy has inspired the exploration of the therapeutic potential of other immune cell types. In this regard, natural killer (NK) cells hold great potential as they can identify tumor cells by mechanisms that are different from those used by T cells and have a high cytotoxic capacity. Their capacity to recognize tumors and killing potency can be further enhanced by genetic modification. Our laboratory has developed a clinically adaptable method to manufacture genetically modified NK cells using retroviral vectors in compliance with current good manufacturing practice regulations. Here, we describe relevant technical procedures, including isolation of peripheral blood mononucleated cells from a leukapheresis product, T-cell depletion, stimulation and transduction of NK cells, and preparation of transduced NK cells for infusion.
- 15 June 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (12_Supplem) , B03
Abstract B03: A phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer
Background: Natural killer cells (NK) are innate immune cells that can kill oncogenically transformed cells. In nasopharyngeal cancer (NPC), epidermal growth factor receptor (EGRF) is highly expressed, and targeted therapy using cetuximab (a chimeric monoclonal based antibody against EGFR) has been used to treat NPC. In this trial, we sought to enhance cetuximab-mediated antibody dependent cellular cytotoxicity (ADCC) by administering it in combination with activated NK cells, which bind the Fc component of the antibody via their surface CD16 receptor. To this end, we applied a method that allows vigorous expansion of activated CD16+ NK cells ex vivo by stimulation with irradiated K562-mb15-41BBL cells. We hypothesized that administration of activated NK cells after cetuximab can increase its anti-NPC activity. Aim: To determine the safety and toxicity profile of sequential cetuximab therapy, followed by concurrent cetuximab with autologous NK cells in patients with refractory nasopharyngeal cancer. Methods: A phase 1, leading on phase 2 study (NCT 02507154) was conducted in patients with recurrent/metastatic nasopharyngeal cancer who had failed at least 2 lines of prior chemotherapy. These patients were scheduled to first receive cetuximab monotherapy for 6-8 weeks, and then cetuximab followed by infusion of expanded and activated autologous NK cells, with 6 doses of subcutaneous IL-2 administered over 1 week to promote NK cell persistence. The primary end point was safety of this combination therapy; secondary endpoint was objective response of measurable disease determined by the RECIST criteria. Results: Seven patients (receiving 10 cetuximab-NK infusions in total) completed the phase 1 trial. The first 3 patients received 1 × 106 NK cells/kg; the dose was escalated to 1 × 107 NK cells/kg and administered to the remaining 4 patients. NK cell expansion, performed over 10 days, produced NK cell numbers that exceeded those planned for infusion in all 7 patients; median number of NK cell recovery was 27,400% of input NK cells (n = 10). ADCC with cetuximab against the cell line SUNE2 was tested 24 hours after NK cell administration and showed median cell killing of 87% (range 56%-95%) in a 4-hour assays at an effector:target ratio of 2:1. All patients tolerated the NK infusion well; no grade 3-4 toxicities were observed. Skin rash was the commonest side effect with cetuximab monotherapy (grade 1-2), which was not aggravated after the administration of cetuximab with NK cells. With a median follow-up of 9 months, we observed 1 partial response, 2 stable diseases, and 4 progressive diseases. Persistence of the quantity and function of NK cells beyond 8 weeks following NK therapy correlated with improved response. Conclusion: Administration of cetuximab with autologous activated CD16+ NK cells at 1 × 107 NK cells/kg is well tolerated in previously heavily treated NPC patients. Grade 1-2 skin toxicity was the predominant side effect, which did not result in termination of this combination therapy. Citation Format: Chwee Ming Lim, Anthony Liou, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Noriko Shimasaki, Dario Campana, Boon Cher Goh. A phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; 2019 Apr 29-30; Austin, TX. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_2):Abstract nr B03.
- 15 June 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (12_Supplem) , B03
Abstract B03: A phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer
Background: Natural killer cells (NK) are innate immune cells that can kill oncogenically transformed cells. In nasopharyngeal cancer (NPC), epidermal growth factor receptor (EGRF) is highly expressed, and targeted therapy using cetuximab (a chimeric monoclonal based antibody against EGFR) has been used to treat NPC. In this trial, we sought to enhance cetuximab-mediated antibody dependent cellular cytotoxicity (ADCC) by administering it in combination with activated NK cells, which bind the Fc component of the antibody via their surface CD16 receptor. To this end, we applied a method that allows vigorous expansion of activated CD16+ NK cells ex vivo by stimulation with irradiated K562-mb15-41BBL cells. We hypothesized that administration of activated NK cells after cetuximab can increase its anti-NPC activity. Aim: To determine the safety and toxicity profile of sequential cetuximab therapy, followed by concurrent cetuximab with autologous NK cells in patients with refractory nasopharyngeal cancer. Methods: A phase 1, leading on phase 2 study (NCT 02507154) was conducted in patients with recurrent/metastatic nasopharyngeal cancer who had failed at least 2 lines of prior chemotherapy. These patients were scheduled to first receive cetuximab monotherapy for 6-8 weeks, and then cetuximab followed by infusion of expanded and activated autologous NK cells, with 6 doses of subcutaneous IL-2 administered over 1 week to promote NK cell persistence. The primary end point was safety of this combination therapy; secondary endpoint was objective response of measurable disease determined by the RECIST criteria. Results: Seven patients (receiving 10 cetuximab-NK infusions in total) completed the phase 1 trial. The first 3 patients received 1 × 106 NK cells/kg; the dose was escalated to 1 × 107 NK cells/kg and administered to the remaining 4 patients. NK cell expansion, performed over 10 days, produced NK cell numbers that exceeded those planned for infusion in all 7 patients; median number of NK cell recovery was 27,400% of input NK cells (n = 10). ADCC with cetuximab against the cell line SUNE2 was tested 24 hours after NK cell administration and showed median cell killing of 87% (range 56%-95%) in a 4-hour assays at an effector:target ratio of 2:1. All patients tolerated the NK infusion well; no grade 3-4 toxicities were observed. Skin rash was the commonest side effect with cetuximab monotherapy (grade 1-2), which was not aggravated after the administration of cetuximab with NK cells. With a median follow-up of 9 months, we observed 1 partial response, 2 stable diseases, and 4 progressive diseases. Persistence of the quantity and function of NK cells beyond 8 weeks following NK therapy correlated with improved response. Conclusion: Administration of cetuximab with autologous activated CD16+ NK cells at 1 × 107 NK cells/kg is well tolerated in previously heavily treated NPC patients. Grade 1-2 skin toxicity was the predominant side effect, which did not result in termination of this combination therapy. Citation Format: Chwee Ming Lim, Anthony Liou, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Noriko Shimasaki, Dario Campana, Boon Cher Goh. A phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; 2019 Apr 29-30; Austin, TX. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_2):Abstract nr B03.
- 28 November 2019
- Published by Springer Nature
- Vol. 2097, 91-105
Engineering of Natural Killer Cells for Clinical Application
The clinical success of chimeric antigen receptor-directed T cells in leukemia and lymphoma has boosted the interest in cellular therapy of cancer. It has been known for nearly half a century that a subset of lymphocytes called natural killer (NK) cells can recognize and kill cancer cells, but their clinical potential as therapeutics has not yet been fully explored. Progress in methods to expand and genetically modify human NK cells has resulted in technologies that allow the production of large numbers of highly potent cells with specific anticancer activity. Here, we describe clinically applicable protocols for NK cell engineering, including expansion of NK cells and genetic modification using electroporation of messenger RNA.
- 28 November 2019
- Published by Springer Nature
- Vol. 2097, 91-105
Engineering of Natural Killer Cells for Clinical Application
The clinical success of chimeric antigen receptor-directed T cells in leukemia and lymphoma has boosted the interest in cellular therapy of cancer. It has been known for nearly half a century that a subset of lymphocytes called natural killer (NK) cells can recognize and kill cancer cells, but their clinical potential as therapeutics has not yet been fully explored. Progress in methods to expand and genetically modify human NK cells has resulted in technologies that allow the production of large numbers of highly potent cells with specific anticancer activity. Here, we describe clinically applicable protocols for NK cell engineering, including expansion of NK cells and genetic modification using electroporation of messenger RNA.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3045
Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC).
3045 Background: A mechanism of Tras is antibody-dependent cell cytotoxicity (ADCC) exerted by NK cells. ADCC may be impaired in cancer patients. We hypothesize that this can be restored by NK activation, and developed a method to generate large numbers of activated NK cells from MBC patients (pts) and tested the effects of NK infusion with Tras. Methods: Peripheral blood harvested from 11 refractory HER2+ MBC pts aged 32-67 (median 59), was co-cultured for 10 days with irradiated K562-mb15-41BBL cells. Expanded NK cells were infused 24 hours (H) post-Tras, with interleukin-2, 1MU/m2 thrice weekly for 6 doses starting 24H pre-infusion. Tras was continued 3 weekly up to 8 cycles (C); pts with sustained stable disease (SD) at C4 or C6 received a 2nd and 3rdinfusion at C6 and C8 respectively. Blood was taken serially for NK cell counts and function. Results: 16 NK cell products were prepared for the 11 pts; 3 pts had a 2nd, and 2 a 3rd infusion. Median NK cell expansion was 337-fold (range 91-478). Products contained 81±16% NK cells, virtually all CD16+ and highly cytotoxic: ADCC on HER2+ SKBR3 cells at 4H with Tras was 85.8±10.1% at 2:1 effector:target ratio (E:T). Pts had 2-13 (median 6) prior lines of palliative therapy. 3 of 16 infusions were at 1st dose level (106 NK cells/kg), and 13 at target dose (107/kg). NK infusion was well tolerated; worst toxicity was transient G2 thrombocytopenia (n = 1). There was no objective response but 7/10 evaluable pts, including 6 who had 107/kg at C1, had SD. Median progression free survival was 1.8 vs 8.5 months for pts who received 106/kg vs 107/kg cells at C1. NK cell counts increased from day (D) 1 (0.16±0.11x103/µL) to D8 (0.32±0.19x103/µL) or D22 post-infusion (0.36±0.20x103/µL) (p < 0.01), although levels were only slightly higher than baseline (0.31±0.22x103/µL). NK cells were 13±8% of PBMCs on D1 and 17±9% on D8; ADCC on SKBR3 cells with Tras without NK enrichment was 11±4% on D1 and 16±5% on D8 (2:1 E:T). Conclusions: This first-in-human study shows that large numbers of highly potent NK cells can be reliably generated from MBC pts and safely infused with Tras. The disease control seen in heavily pre-treated pts is encouraging and warrants further studies. Clinical trial information: NCT02030561.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3045
Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC).
3045 Background: A mechanism of Tras is antibody-dependent cell cytotoxicity (ADCC) exerted by NK cells. ADCC may be impaired in cancer patients. We hypothesize that this can be restored by NK activation, and developed a method to generate large numbers of activated NK cells from MBC patients (pts) and tested the effects of NK infusion with Tras. Methods: Peripheral blood harvested from 11 refractory HER2+ MBC pts aged 32-67 (median 59), was co-cultured for 10 days with irradiated K562-mb15-41BBL cells. Expanded NK cells were infused 24 hours (H) post-Tras, with interleukin-2, 1MU/m2 thrice weekly for 6 doses starting 24H pre-infusion. Tras was continued 3 weekly up to 8 cycles (C); pts with sustained stable disease (SD) at C4 or C6 received a 2nd and 3rdinfusion at C6 and C8 respectively. Blood was taken serially for NK cell counts and function. Results: 16 NK cell products were prepared for the 11 pts; 3 pts had a 2nd, and 2 a 3rd infusion. Median NK cell expansion was 337-fold (range 91-478). Products contained 81±16% NK cells, virtually all CD16+ and highly cytotoxic: ADCC on HER2+ SKBR3 cells at 4H with Tras was 85.8±10.1% at 2:1 effector:target ratio (E:T). Pts had 2-13 (median 6) prior lines of palliative therapy. 3 of 16 infusions were at 1st dose level (106 NK cells/kg), and 13 at target dose (107/kg). NK infusion was well tolerated; worst toxicity was transient G2 thrombocytopenia (n = 1). There was no objective response but 7/10 evaluable pts, including 6 who had 107/kg at C1, had SD. Median progression free survival was 1.8 vs 8.5 months for pts who received 106/kg vs 107/kg cells at C1. NK cell counts increased from day (D) 1 (0.16±0.11x103/µL) to D8 (0.32±0.19x103/µL) or D22 post-infusion (0.36±0.20x103/µL) (p < 0.01), although levels were only slightly higher than baseline (0.31±0.22x103/µL). NK cells were 13±8% of PBMCs on D1 and 17±9% on D8; ADCC on SKBR3 cells with Tras without NK enrichment was 11±4% on D1 and 16±5% on D8 (2:1 E:T). Conclusions: This first-in-human study shows that large numbers of highly potent NK cells can be reliably generated from MBC pts and safely infused with Tras. The disease control seen in heavily pre-treated pts is encouraging and warrants further studies. Clinical trial information: NCT02030561.